购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空
筛选
已筛选:全部清除
TargetMol | Tags 通过 靶点 筛选
  • Apoptosis
    (3)
  • Potassium Channel
    (3)
  • Epigenetic Reader Domain
    (2)
  • HIV Protease
    (2)
TargetMol | Tags 通过 货期 筛选
  • 现货
    (15)
  • 5日内发货
    (28)
  • 7日内发货
    (2)
  • 20日内发货
    (1)
筛选
搜索结果
TargetMol产品目录中 "

k 13

"的结果
  • 抑制剂&激动剂
    64
    TargetMol | Inhibitors_Agonists
  • 重组蛋白
    7
    TargetMol | Recombinant_Protein
  • 多肽产品
    6
    TargetMol | Peptide_Products
  • 抗体抑制剂
    1
    TargetMol | Inhibitory_Antibodies
  • 染料试剂
    1
    TargetMol | Dye_Reagents
  • PROTAC
    1
    TargetMol | PROTAC
  • 天然产物
    4
    TargetMol | Natural_Products
  • 检测抗体
    23
    TargetMol | Antibody_Products
K-13
K-13 (Ace inhib)
T25564108890-90-0
K-13 is used as an ACE inhibitor produced by Micromonospora halophytics subsp. exilisia K-13.
  • ¥ 10600
期货
规格
数量
K 13-004
K 13004,K13004
T3234696609-38-0
K 13-004 is a lipid-lowering agent.
  • ¥ 10600
6-8周
规格
数量
8K13-hz35-STING-D4-1203
T894482228893-47-6
8K13-hz35-STING-D4-1203 为一种ADC(药物-连接子偶联物).
  • 待询
规格
数量
PI3Kα-IN-13
T796852955529-67-4
PI3Kα-IN-13(Compound 18a)是一款高效的PI3Kα抑制剂,具有2.5 nM的IC50值。此化合物能够诱发肿瘤细胞的凋亡,并显著抑制癌细胞的增殖,具体IC50值为MCF-7细胞系0.75 μM、HCT-116细胞系3.79 μM、MDA-MB-231细胞系13.71 μM和SW620细胞系9.85 μM。此外,PI3Kα-IN-13能有效阻止肿瘤细胞集落的形成、迁移以及侵袭。
  • ¥ 10600
6-8周
规格
数量
PI3Kδ-IN-13
T796271686137-02-9
PI3Kδ-IN-13(化合物89)是一种高效的PI3Kδ抑制剂,其IC50值为2.6 nM。该化合物主要用于研究癌症、感染、炎症以及自身免疫性病变等涉及细胞增殖的疾病。
  • 待询
8-10周
规格
数量
PI3K/mTOR Inhibitor-13
T723801621718-37-3
PI3K mTOR Inhibitor-13 是一种具有口服活性的磷酸肌醇 3-激酶 (PI3K) 和mTOR 激酶双重抑制剂。PI3K mTOR Inhibitor-13 在性疾病、实体瘤和特发性肺纤维化 (IPF) 中有潜在应用。
  • ¥ 10600
6-8周
规格
数量
PK 130
PK130,PK-130
T34083140448-29-9
PK 130, as a hypoxic cell radiosensitizer, is an L-phenylalanine methyl ester conjugate of 2-nitroimidazol.
  • ¥ 10600
6-8周
规格
数量
ZK 136295
ZK-136295, ZK136295, CYCLOTRIOL
T202164135768-83-1
ZK 136295是一种新型雌激素。在口服时,其系统可用性表现出与ethinylestradiol相似的降低和高度变异性。ZK 136295的剂量加倍可增加其系统可用性,这突显了剂量在提高生物利用度中的重要性。
  • 待询
10-14周
规格
数量
IEIK 13
T820811426415-02-2
IEIK 13为一种自组装肽(SAP)序列,适用于软骨组织工程研究领域。
  • 待询
规格
数量
TAK-137
TAK137
T708801358749-55-9In house
TAK-137 是一种 AMPA 受体增强剂,具有抗抑郁作用。TAK-137 具有改善认知的能力,可用于研究神经分裂症。
  • ¥ 1980
现货
规格
数量
TargetMol | Inhibitor Hot
EUK-134
EUK 134, 乙基双亚氨基甲基愈创木酚锰氯化物
T649581065-76-1
EUK-134 是合成的超氧化物歧化酶和过氧化氢酶模拟物,可保护大鼠肾脏免受缺血再灌注引起的损伤。它作用于 H9C2 细胞,降低NF-κB 表达、MDA 水平和蛋白质羰基化。它是具有过氧化氢酶活性的超氧化物歧化酶 (SOD) 模拟物 (SODm)。它是保护有丝分裂的抗氧化剂。
  • ¥ 139
现货
规格
数量
Dolutegravir sodium
度鲁特韦钠, GSK1349572, 度鲁特韦钠盐, GSK-1349572A
T23291051375-19-9
Dolutegravir sodium (GSK-1349572A) 是一种高效、口服的 HIV 整合酶链转移抑制剂,在 HIV-1 整合酶催化的链转移中的 IC50值为 2.7 nM, 抑制 HIV-1 病毒在外周血单个核细胞中的复制,IC50为 0.51 nM。它对 Y143R,N155H 和 G140S Q148H 突变体也保持高效。
  • ¥ 378
现货
规格
数量
Dolutegravir
S GSK1349572, 度鲁特韦, GSK1349572, 多替拉韦
T61981051375-16-6
Dolutegravir (GSK1349572) 是口服HIV 整合酶链转移高效抑制剂,抑制 HIV-1 病毒在外周血单个核细胞中的复制。它对耐拉替拉韦的特征突变体 Y143R、Q148K、N155H 和 G140S Q148H 具有中等活性。
  • ¥ 386
现货
规格
数量
TargetMol | Citations 客户已引用
GSK137647A
GSK 137647
T3171349085-82-1
GSK137647A (GSK 137647) 是一种选择性FFA4激动剂,作用于人类和大小鼠FFA4的pEC50分别为6.3、6.1和6.2。
  • ¥ 186
现货
规格
数量
TargetMol | Citations 客户已引用
Foretinib
XL880, GSK1363089, GSK089, EXEL-2880
T3113849217-64-7
Foretinib (GSK1363089) 是多靶点酪氨酸激酶抑制剂,能够抑制 Met (IC50:0.4 nM) 和 KDR (IC50:0.9 nM)。
  • ¥ 342
现货
规格
数量
TargetMol | Citations 客户已引用
GSK1379725A
T154241802251-00-8
GSK1379725A 是一种选择性 BPTF 配体,Kd 为 2.8 μM。
  • ¥ 518
现货
规格
数量
TargetMol | Inhibitor Sale
GSK1324726A
I-BET726
T60211300031-52-0
GSK1324726A (I-BET726) 是一种选择性有效的BET 蛋白抑制剂,高亲和力结合到BRD2、BRD3和BRD4,IC50值分别为 41 nM、31 nM 和 22 nM。
  • ¥ 189
现货
规格
数量
TargetMol | Inhibitor Sale
Anti-Mouse NK1.1 Antibody (PK136)
T78268
Anti-Mouse NK1.1 Antibody (PK136) 是鼠源靶向 NK1.1的IgG2a类抗体,可消除外周血、脾脏和肺组织中的NK1.1和NK1.1NKT细胞,抑制 NK1.1 信号传导,可用于研究心肺衰竭。
  • ¥ 2090
现货
规格
数量
Gadoxetate Disodium
钆塞酸二钠, ZK 139834, Gd-EOB-DTPA Disodium
T15367135326-22-6
Gadoxetate Disodium 是一种肝胆系统中磁共振成像 (MRI) 中的造影剂,能够在正常的功能性肝细胞中累积,可用于局灶性肝脏病变(如肝细胞癌或 T1 加权成像的肝转移)的研究。
  • ¥ 147
现货
规格
数量
TargetMol | Inhibitor Sale
MAPK13-IN-1
T11943229002-10-2
MAPK13-IN-1 是一种有效的 MAPK13 (p38δ) 抑制剂(IC50:620 nM)。
  • ¥ 1180
现货
规格
数量
LL-37 FK-13 TFA
TP2808
LL-37 FK-13TFA 代表LL-37 FK-13的TFA盐状态.这种化合物主要用作抗菌剂,有效抑制Trichomonas vaginalis.与此同时,LL-37 FK-13 TFA对人类红细胞展示出轻微的溶血性,对人类成纤维细胞的细胞毒性也相对较弱.
  • 待询
规格
数量
Milvexian TFA
T701701802426-00-1
Milvexian, also known as BMS-986177 and JNJ-70033093, is a blood coagulation factor XIa inhibitor. Milvexian demonstrated good selectivity over plasma kallikreinKi = 44 nM (400-fold selective), and chymotrypsinKi = 35 nM (318-fold selective). At a dose of 1.5 mg kg, Milvexian exhibited an overall exposure of 1215 nM h, low clearance of 10.3 mL min kg, and oral bioavailability of 32%.
  • ¥ 10600
6-8周
规格
数量
JQ1-Acid HCl
T707021426257-60-4
(+)-JQ-1 carboxylic acid is a potent bromodomain and extra terminal domain (BET) inhibitor. (+)-JQ-1 carboxylic has potential to be used as a precursor to synthesize PROTACs and other conjugates.
  • ¥ 10600
6-8周
规格
数量
DK-139
T707031426059-23-5
DK-139 is an inhibitor of NF-kappaB-mediated GROalpha expression, suppressing the TNFalpha-induced invasive capability of MDA-MB-231 human breast cancer cells.
  • ¥ 10600
6-8周
规格
数量
YOK-1304
T885692409960-03-6
YOK-1304 是一款针对自噬的AUTOTAC嵌合体,能够诱导p62进行自我寡聚化。
  • 待询
10-14周
规格
数量
GSK1331268
GSK 1331268,GSK-1331268
T274491207197-70-3
GSK1331268 is a selective, orally bioavailable positive modulators of mGluR2.
  • ¥ 10600
6-8周
规格
数量
GK13S
T75182
G13KS 是一种去泛素化酶UCHL1配体和抑制剂。G13KS 抑制重组和细胞 UCHL1。G13KS 降低人胶质母细胞瘤细胞中单泛素的水平。
  • 待询
规格
数量
P516-0475
T708781359627-33-0
P516-0475 is a novel chemical inducer of Streptococcus quorum sensing acts by inhibiting the pheromone-degrading endopeptidase PepO. This compound induces quorum sensing by stabilizing SHP pheromones in culture.
  • ¥ 10600
6-8周
规格
数量
GSK1370319A
T716511001389-31-6
GSK1370319A is a potent P2X7 antagonist (IC50 = 3.2 nM). GSK1370319A inhibits ATP-induced increase in IL-1β release and caspase 1 activation in lipopolysaccharide (LPS)-primed mixed glia by blocking assembly of the inflammasome in a pannexin 1-dependent manner. GSK1370319A also inhibits ATP-induced subregion-specific neuronal loss in hippocampal organotypic slice cultures, which is dependent on its ability to prevent inflammasome assembly in glia. Significantly, GSK1370319A attenuates age-related deficits in long-term potentiation (LTP) and inhibits the accompanying age-related caspase 1 activity. We conclude that inhibiting P2X(7) receptor-activated NLRP3 inflammasome formation and the consequent IL-1β release from glia preserve neuronal viability and synaptic activity.
  • ¥ 10600
6-8周
规格
数量
SCR1693
T706401442559-20-7
SCR1693 is a dual acetylcholinesterase inhibitor (AChEI) and a calcium channel blocker (CCB).
  • ¥ 10600
6-8周
规格
数量
K134
OPC33509
T15640189362-06-9
K134 is an inhibitor of phosphodiesterase 3. The IC50s of K134 for PDE3A, PDE3B, PDE5, PDE2 and PDE4 are 0.1, 0.28, 12.1, >300 and >300 μM, respectively.
  • ¥ 3190
5日内发货
规格
数量
GSK1379767A
T701711802251-02-0
GSK1379767A is a dual inhibitor of BPTF and Brd4.
  • ¥ 10600
6-8周
规格
数量
GSK1360707
GSK-1360707,GSK 1360707
T254671013098-04-8
GSK1360707 is a selective triple reuptake inhibitor (TRI).
  • ¥ 12800
8-10周
规格
数量
AK-135
T2979275397-64-7
AK-135 is a derivative of 1,4-naphthoquinone (Menadione). AK-135 has been shown to restore the electron flow in defective respiratory chain (hypoxia or rotenone) systems more effectively than Menadione.
  • ¥ 10600
期货
规格
数量
GSK1331258
GSK 1331258,GSK-1331258
T274481207197-68-9
GSK1331258 is a selective, orally bioavailable positive modulators of mGluR2.
  • ¥ 10600
6-8周
规格
数量
GK-136901
T715131062624-71-8
GK-136901 is a first-in-class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitor.
  • ¥ 10600
6-8周
规格
数量
cyclo(RLsKDK)
BK-1361
T729051975145-82-4
Cyclo(RLsKDK) (BK-1361) 作为ADAM8金属蛋白酶的特异性抑制剂,展示出182 nM的IC50值。其在炎性疾病和癌症治疗中显示出潜在的应用价值。
  • ¥ 10600
6-8周
规格
数量
ICI-185282
T71511106393-80-0
ICI-185282 is a potent thromboxane receptor antagonist.
  • ¥ 15000
8-10周
规格
数量
Chloroprocaine hydrochloride
盐酸氯普鲁卡因, Chloroprocaine HCl
T64433858-89-7
Chloroprocaine hydrochloride (Chloroprocaine HCl) 是一种 Na K-ATPase 活性抑制剂,IC50为 13 mM,可阻断外周神经。
  • ¥ 148
现货
规格
数量
TargetMol | Inhibitor Sale
Doxapram
多沙普仑, Dopram
T22315309-29-5
Doxapram (Dopram) 是一种呼吸兴奋剂,抑制 TASK-1,TASK-3 和 TASK-1 TASK-3 异二聚体通道,可用于研究早产儿呼吸暂停和慢性阻塞性肺疾病恶化引起的通气衰竭。
  • ¥ 108
现货
规格
数量
2,5-dimethyl Celecoxib
2,5-二甲基塞来考昔
T35610457639-26-8
2,5-dimethyl Celecoxib 是塞来昔布衍生物和微粒体前列腺素 E 合酶 1 (mPGES-1) 的靶向抑制剂,mPGES-1 是炎症介质 PGE2 合成途径中的关键酶。
  • ¥ 562
现货
规格
数量
CDDD11-8
T860252241659-94-7
CDDD11-8 is an orally administered, highly potent and selective CDK9 and FLT3-ITD inhibitor, with K i values of 8 nM and 13 nM, respectively. It effectively reduces the proliferation of leukemia cell lines, showing particular efficacy against those with the FLT3-ITD mutation [1] [2].
  • 待询
10-14周
规格
数量
RGH-122
T873182355304-05-9
RGH-122 (compound 43)是一种口服活性良好、选择性高、有效的V1a拮抗剂,Ki值为0.3 nM。
  • 待询
10-14周
规格
数量
Ibuprofen Impurity K
T4053743153-07-7
Ibuprofen Impurity K is a compound that serves as an impurity in Ibuprofen. Ibuprofen itself is an anti-inflammatory inhibitor specifically designed to target COX-1 and COX-2. It exhibits inhibitory activity with IC50 values of 13 μM and 370 μM for COX-1 and COX-2, respectively.
  • ¥ 1997
5日内发货
规格
数量
7(S),17(S)-dihydroxy-8(E),10(Z),13(Z),15(E),19(Z)-Docosapentaenoic Acid
T36999887752-13-8
Novel oxylipins, referred to as docosanoids, have been derived from C22polyunsaturated fatty acids 7(S),17(S)-dihydroxy-8(E),10(Z),13(Z),15(E),19(Z)-Docosapentaenoic acid (7(S),17(S)-hydroxy DPA) is a DPA-derived analog of the 17(S)-dihydroxy series of docosanoids known as protectins. Protectin D1, a DHA-derived dihydroxy fatty acid, exhibits potent anti-inflammatory activities.1,2,3Potentially, 7(S),17(S)-hydroxy DPA demonstrates similar properties; however, its biological activity has yet to be determined. 1.Serhan, C.N., Gotlinger, K., Hong, S., et al.Anti-inflammatory actions of neuroprotectin D1 protectin D1 and its natural stereoisomers: Assignments of dihydroxy-containing docosatrienesJ. Immunol.176(3)1848-1859(2006) 2.Ariel, A., and Serhan, C.N.Resolvins and protectins in the termination program of acute inflammationTRENDS in Immunology28(4)176-183(2007) 3.Schwab, J.M., Chiang, N., Arita, M., et al.Resolvin E1 and protectin D1 activate inflammation-resolution programmesNature447(7146)869-874(2007)
  • 待估
35日内发货
规格
数量
[Lys8, Lys9]-Neurotensin (8-13)
JMV438,[Lys8, Lys9]-Neurotensin (8-13)
T38807139026-64-5
[Lys8, Lys9]-Neurotensin (8-13) (JMV438) is a Neurotensin analog that elicits analgesic effects by activating the G protein-coupled receptors NTS1 and NTS2. The compound has K i values of 0.33 nM and 0.95 nM for hNTS1 and hNTS2 receptors, respectively.
  • 待询
规格
数量
Hemitoxin
T80436
Hemitoxin为一种蝎毒肽,作用于K+通道阻滞剂。其能够阻断表达于非洲爪蟾卵母细胞的大鼠Kv1.1、Kv1.2和Kv1.3通道,对应IC50值为13 nM、16 nM及2 nM。
  • 待询
规格
数量
Urocortin III (human) (trifluoroacetate salt)
T35814
Urocortin III is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin II , frog sauvagine, and piscine urotensin I.1 Human urocortin III shares 90, 40, 37, and 21% identity to mouse urocortin III , mouse urocortin II , human urocortin , and mouse urocortin, respectively. Urocortin III selectively binds to type 2 CRF receptors (Kis = 21.7, 13.5, and >100 nM for rat CRF2α, rat CRF2β, and human CRF1, respectively). It stimulates cAMP production in CHO cells expressing rat CRF2α and mouse CRF2β (EC50s = 0.16 and 0.12 nM, respectively) as well as cultured anterior pituitary cells expressing endogenous CRF2β. Urocortin III is co-released with insulin to potentiate glucose-stimulated somatostatin release in vitro in human pancreatic β-cells.2 In vivo, urocortin III reduces food intake in a dose- and time-dependent manner in mice with a minimum effective dose (MED) of 0.3 nmol/animal.3 It increases swimming time in a forced swim test in mice, indicating antidepressant-like activity.4References1. Lewis, K., Li, C., Perrin, M.H., et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A. 98(13), 7570-7575 (2001).2. van der Meulen, T., Donaldson, C.J., Cáceres, E., et al. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nat. Med. 21(7), 769-776 (2015).3. Pelleymounter, M.A., Joppa, M., Ling, N., et al. Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides 25(4), 659-666 (2004).4. Tanaka, M., Kádár, K., Tóth, G., et al. Antidepressant-like effects of urocortin 3 fragments. Brain Res. Bull. 84(6), 414-418 (2011). Urocortin III is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin II , frog sauvagine, and piscine urotensin I.1 Human urocortin III shares 90, 40, 37, and 21% identity to mouse urocortin III , mouse urocortin II , human urocortin , and mouse urocortin, respectively. Urocortin III selectively binds to type 2 CRF receptors (Kis = 21.7, 13.5, and >100 nM for rat CRF2α, rat CRF2β, and human CRF1, respectively). It stimulates cAMP production in CHO cells expressing rat CRF2α and mouse CRF2β (EC50s = 0.16 and 0.12 nM, respectively) as well as cultured anterior pituitary cells expressing endogenous CRF2β. Urocortin III is co-released with insulin to potentiate glucose-stimulated somatostatin release in vitro in human pancreatic β-cells.2 In vivo, urocortin III reduces food intake in a dose- and time-dependent manner in mice with a minimum effective dose (MED) of 0.3 nmol/animal.3 It increases swimming time in a forced swim test in mice, indicating antidepressant-like activity.4 References1. Lewis, K., Li, C., Perrin, M.H., et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A. 98(13), 7570-7575 (2001).2. van der Meulen, T., Donaldson, C.J., Cáceres, E., et al. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nat. Med. 21(7), 769-776 (2015).3. Pelleymounter, M.A., Joppa, M., Ling, N., et al. Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides 25(4), 659-666 (2004).4. Tanaka, M., Kádár, K., Tóth, G., et al. Antidepressant-like effects of urocortin 3 fragments. Brain Res. Bull. 84(6), 414-418 (2011).
  • ¥ 7043
期货
规格
数量